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H I G H L I G H T S
• Changes in synaptic protein levels provide insight into synaptic reorganisation in epilepsy.• In the RISE model changes in GluR subunits occur at different stages of epileptogenesis.• Changes appear to occur independently of changes in synapse number.• GluR profiles are directly linked to changes in network excitability.• Targeting GluR subunits could provide a new strategy to reduce seizures.
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A B S T R A C T
The RISE model is an effective system to study the underlying molecular and cellular mechanisms involved in the
initiation and maintenance of epilepsy in vivo. Here we profiled the expression of excitatory and inhibitory
neurotransmitter receptor subunits and synaptic scaffolding proteins in the hippocampus and temporal lobe and
compared these changes with alterations in network activity at specific timepoints during epileptogenesis.
Significant changes occurred in all of the ionotropic glutamate receptor subunits tested during epilepsy induction
and progression and the profile of these changes differed between the hippocampus and temporal lobe. Notably,
AMPAR subunits were dramatically decreased during the latent phase of epilepsy induction, matched by a
profound decrease in the network response to kainate application in the hippocampus. Moreover, decreases in
the GABAAβ3 subunit are consistent with a loss of inhibitory input contributing to the perturbation of excitatory/
inhibitory balance and seizure generation. These data highlight the synaptic reorganisation that mediates the
relative hypoexcitability prior to the manifestation of seizures and subsequent hyperexcitability when sponta-
neous seizures develop. These patterns of changes give new insight into the mechanisms underpinning epilepsy
and provide a platform for future investigations targeting particular receptor subunits to reduce or prevent
seizures.
1. Introduction
Epilepsy is characterised by recurrent seizures caused by excessive
neuronal activity in susceptible brain regions. Up to ~1% of the po-
pulation worldwide suffer from epilepsy, equating to ~50 million
people and, of these, ~40% have Temporal Lobe Epilepsy (TLE).
Although epilepsy can often be controlled with medication, ~30% of
epilepsy cases are resistant to anti-epileptic drugs (AEDs) (WHO, 2018).
Furthermore, approximately a third of those initially responsive to
AEDs will transition to drug-resistant epilepsy (DRE) during the course
of the disease (Devinsky et al., 2018).
There is an extensive, and sometimes contradictory, literature sur-
rounding epileptogenesis and progression of TLE (for recent reviews see
(Becker, 2018; Fukata and Fukata, 2017)). Notwithstanding the many
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unresolved questions, it is now widely accepted that synaptic function
is dynamically scaled in response to activity (homeostatic synaptic
scaling) and that dysfunction of receptors and/or their signalling
pathways play key roles in disrupting the excitatory/inhibitory balance
that underpins epilepsy (Badawy et al., 2012).
Systemic or local insult can cause vulnerable brain regions to de-
velop spontaneous recurrent seizures. Many studies assess changes
during the status epilepticus period of intense seizure activity, which is
often associated with high mortality and/or global damage to large
areas of the brain. Reduced Intensity Status Epilepticus (RISE) is a low
mortality, high morbidity rat model of chronic TLE characterised by a
relatively long seizure-free (latent) period between induction and the
development of spontaneous recurrent seizures (SRS) (Modebadze
et al., 2016). Importantly, RISE replicates some of the core features of
human temporal lobe epilepsy including restriction to temporal lobe
structures, variation in seizure frequency and intensity between animals
and slow periodic variations in seizure activity. Moreover, RISE avoids
the gross neuronal damage that may be seen with alternative models,
showing comparatively low levels of neuronal damage in the hippo-
campus (Modebadze et al., 2016).
There have, however, been no biochemical analyses of the expres-
sion levels of key neuronal proteins in RISE rats. To gain insight into
molecular changes that occur during the initiation, development and
establishment of epilepsy, we systematically profiled an array of sy-
naptic receptor proteins in the hippocampus and the temporal lobe of
RISE rats and non-epileptic age-matched controls (AMC). The time
points sampled were: 24 h after injection with pilocarpine, when rats
are recovering from the initial Status Epilepticus (SE) phase; 2–4 weeks
after pilocarpine injection, when the rats are in a latent period (LP); and
the chronic phase following the onset of spontaneous recurrent seizures
(SRS), usually 3+ months after pilocarpine injection.
There were changes in many of the proteins tested, most of which
display reduced levels in RISE compared to AMC rats. In particular, we
detected highly significant reductions in levels of AMPAR subunits.
However, the expression levels of some proteins, notably the NMDAR
subunit GluN1 and the excitatory synaptic marker PSD95, increased at
specific phases of epilepsy. The alterations in protein levels throughout
epilepsy progression differed between the hippocampus and the tem-
poral lobe. Moreover, the changes in receptor expression were con-
sistent with alterations in neuronal network excitability in hippocampal
area CA3, as measured using a kainate challenge protocol that defines
peak excitability in response to application of 100 nM kainate against a
baseline measure of network oscillatory power made without kainate
application.
2. Materials and methods
2.1. Generation of the In Vivo RISE model of epilepsy
RISE rats were generated at Aston University as reported previously
(Modebadze et al., 2016). Detailed methods are provided in Supple-
mental Material. Three timepoints during epilepsy progression were
sampled in RISE rats and age-matched controls (AMC):
1) Status Epilepticus (SE); rats were sacrificed 24 h post-induction with
pilocarpine.
2) Latent period (LP); rats were sacrificed 2–4 weeks after SE induc-
tion, corresponding to the latent, seizure-free phase of epilepsy.
3) Spontaneous recurrent seizures (SRS); rats were sacrificed
3+ months post-induction of SE immediately following the devel-
opment of spontaneous recurrent seizures, as determined by beha-
vioural tests and/or video recording of behaviour (Modebadze et al.,
2016).
2.2. Western blotting
Samples of hippocampus and temporal lobe dissected from four or
five individual RISE and AMC rats containing 40 μg of total protein
were run in parallel on the same 10% SDS-PAGE gel and im-
munoblotted along with loading controls of either β-actin, β-tubulin III
or α-GAPDH, depending on the MW of the protein investigated. At least
two technical repeats were performed. After protein transfer, PVDF
membranes were blocked and probed with appropriate primary and
secondary antibody (Supplemental Material, Table 1) and quantita-
tively imaged using an Odyssey Imaging System (LI-COR). Importantly,
this dymanic quantitification system removes the possibility of any
error due to overexposure of the Western blot that can occur using film
based analysis.
2.3. Electrophysiology
Animals were taken at specific timepoints during epileptogenesis
and brain slices prepared using standard techniques. Spontaneous
gamma (SγO) and kainic acid-induced (KγO) oscillations were recorded
from CA3 of the hippocampus. Detailed methods are provided in the
Supplemental Material. Animals were visusally monitored prior to, and
during, anaesthesia to ensure that acute seizures did not occur within
the 60minutes immediately before preparation for slices or blotting.
2.4. Statistical methods
Standard statistical tests were used and further details are provided
in the Supplemental Material.
3. Results
3.1. Synaptic marker proteins
We first investigated levels of the presynaptic marker synapto-
physin, the excitatory postsynaptic marker PSD95 and the inhibitory
postsynaptic marker gephyrin in hippocampus and temporal lobe
samples at SE, LP and SRS stages of epilepsy (Fig. 1). There were no
significant changes in synaptophysin in the hippocampus or temporal
lobe at any stage of epilepsy. Similarly, there were no differences in
PSD95 or gephyrin levels at any timepoint in the temporal lobe.
However, there were highly significant changes in the levels of PSD95
in the hippocampus where PSD95 decreased by ~30% in SE and ~50%
in LP compared to AMC but, in stark contrast, there was a 3-fold in-
crease in SRS (Fig. 1). Interestingly, we also detected a significant in-
crease in gephyrin during the latent phase (LP) but no change in any
other stage in the hippocampus.
3.2. Neurotransmitter receptors
In parallel, we determined the levels of a range of neurotransmitter
receptor proteins that have been implicated in epilepsy in hippocampus
and temporal lobe samples. We measured total levels of the most
abundant AMPAR and kainate receptor (KAR) subunits (GluA1, GluA2,
GluA3 (Henley and Wilkinson, 2016) and GluK2, GluK5 (Evans et al.,
2017) respectively); the obligatory NMDAR subunit GluN1 and the
GluN2A and GluN2B subunits that play a role in determining NMDAR
localisation and function (Paoletti et al., 2013); metabotropic glutamate
receptors mGluR1α and mGluR5 (Suh et al., 2018); the presynaptic
cannabinoid receptor CB1 (Busquets Garcia et al., 2016); and the most
prevalent subunit of inhibitory GABAARs, GABAAβ3 (Sieghart and
Savic, 2018). Representative Western blots and quantification for pro-
teins that showed changes in hippocampus and temporal lobe are pre-
sented in Fig. 2 and Fig. 3 respectively. Blots and quantification for
proteins that did not change significantly are shown in Supplemental
Figs. 1 and 2.
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3.3. Hippocampus
3.3.1. Timepoint 1; SE
Consistent with previously reported work on hippocampal sclerosis
in epilepsy (Sendrowski and Sobaniec, 2013), we observed multiple
changes in protein levels. Immediately following SE, the AMPAR sub-
unit GluA1 was decreased by 40% but there were no corresponding
reductions in GluA2 or GluA3 compared to AMC at this initial time-
point. These data suggest a selective loss of GluA1 containing AMPARs
during early phase TLE, with minimal effects of GluA2/GluA3 hetero-
meric AMPARs.
There was also a ~35% reduction in the KAR subunit GluK2 with no
significant change in GluK5. Levels of mGluR1α and GABAAβ3 were
also significantly reduced whereas no significant changes were detected
for the NMDAR subunits GluN1, GluN2A or GluN2B (Supplemental
Fig. 1).
3.3.2. Timepoint 2; LP
During the latent phase the AMPAR subunits (GluA1, GluA2 and
GluA3) were all dramatically reduced in the hippocampus. Remarkably,
GluA1 was reduced by ~80% compared to AMC rats. In addition, al-
though unchanged immediately following SE, levels of GluA2 and
GluA3 reduced by ~50% and ~40% respectively during LP.
Interestingly, after the initial SE timepoint, levels of GluK2 did not
change compared to AMC rats, suggesting a recovery in expression of
this KAR subunit. The only other significant change was a decrease in
GluN2A, which was not observed in SE.
3.3.3. Timepoint 3; SRS
At this timepoint, most RISE animals show electrographic and be-
havioural evidence of seizure activity and so it was surprising that le-
vels of GluA1, GluA2 and GluA3 AMPAR subunits in the hippocampus
remained very substantially reduced compared to AMC rats following
the onset of spontaneous seizures. In addition, levels of GluN2A also
remained decreased during SRS (Fig. 2 & Supplemental Fig. 1), while
the levels of GABAAβ3, that initially decreased in the SE phase but re-
mained unchanged during LP phase, decreased significantly in this
phase.
3.4. Temporal lobe
3.4.1. Timepoint 1; SE
In contrast to our observations in the hippocampus, there was no
significant decrease in the AMPAR subunit GluA1 but there were sig-
nificant reductions in GluA2 and GluA3 (Fig. 3 & Supplemental Fig. 2).
The only other significant changes at this timepoint in the temporal
lobe were decreases in GluN2A and GABAAβ3.
3.4.2. Timepoint 2; LP
During the latent period none of the AMPAR subunits were altered
compared to AMC samples. However, GluN1 decreased by ~50% in
RISE compared to AMC rats along with a significant decrease in
GluN2A. Since GluN1 is obligatory for functional NMDAR complexes
we speculate that this would lead to reduced NMDAR-mediated sy-
naptic transmission during LP.
In addition, we detected a 40% decrease in levels of the KAR subunit
GluK5 but no change in GluK2, consistent with a change in the subunit
stoichiometry of KAR complexes in the temporal lobe during the latent
period.
3.4.3. Timepoint 3; SRS
Despite being unchanged during LP, temporal lobe levels of two of
the AMPAR subunits (GluA1 and GluA2, but not GluA3) were sub-
stantially decreased in SRS. Indeed, similar to the hippocampal sam-
ples, GluA1 was reduced by ~80% compared to AMC rat levels.
Correspondingly, GluA2 was also significantly reduced. In addition,
mGluR1α and mGluR5 were significantly decreased, as were levels of
the NMDAR subunits GluN2A and GluN2B, but not of GluN1 (Fig. 3).
3.5. Overview of changes detected in the three stages of epilepsy in RISE rats
An overview of the profiles of changes in RISE compared to AMC
rats is shown in Fig. 4. However, prominent exceptions were the pro-
nounced increase in PSD95 in the hippocampus, but not in the temporal
lobe, in SRS as well as the timing of the differential loss in AMPAR
subunits between these two brain regions.
Our data highlight the fact that GABAAβ3 and gephyrin have a very
similar expression profile in the hippocampus. More specifically, these
inhibitory synapse proteins are decreased during active seizure stages
(SE and SRS) but not during the seizure free LP stage of epilepsy. Taken
together, these data are consistent with a deficit in inhibitory neuro-
transmission contributing to seizure activity.
Fig. 1. Levels of synaptic marker proteins in hippocampus and temporal
lobe in AMC and RISE rats at different stages of epileptogenesis.
RISE rats were sacrificed 24 h (SE), 2–4 weeks (LP) or ~3+ months (SRS) post
pilocarpine injection and hippocampi and temporal lobes dissected, im-
mediately flash frozen in liquid nitrogen and stored at −80 °C until use.
Samples were homogenised, protein matched and 40 μg of total protein was
loaded per lane.
Left panels: Representative Western blots of hippocampal and temporal lobe
samples from 4 (SE) or 5 (LP and SRS) separate AMC and RISE rats im-
munoblotted for synaptophysin, PSD95 and gephyrin. β-tubulin III and β-actin
were used as loading controls.
Right panels: Quantification of immunoreactive bands normalised to their re-
spective loading controls. Error bars represent the mean ± SD from 4 samples,
with the mean of the control group set to 1. *P < 0.05 vs Ctrl, **P < 0.01 vs
Ctrl, ***P< 0.001 vs Ctrl (Unpaired t-test).
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3.6. Correlation between changes in receptor and synaptic marker protein
abundance
To exclude the possibility that the differences in receptor proteins
simply reflected changes in the numbers of synapses, we performed
correlation analyses. As shown by the line plots in Fig. 5 (statistical
analysis in Supplemental Table 2), there was no correlation between
changes in synaptic marker proteins and receptor proteins. It should be
noted that Western blotting captures total levels of protein in the cell
and that only a proportion of neurotransmitter receptors are surface
expressed at any particular time; for example ~50% for GluA2
(Perestenko and Henley, 2006). Moreover, because surface expressed
receptors can be highly laterally mobile within the plasma membrane,
at any given timepoint and depending on the synaptic activity, only a
sub-population of AMPARs are present at synapses. Thus, it is not
surprising that our data imply that changes in total levels of receptor
proteins occur independently of changes in synapse number. These
results are consistent with the changes in receptors we observe playing
mechanistic causal roles in, rather than simply being a downstream
consequence of, the epileptogenic process and neuronal feedback re-
sponses to increased activity.
3.7. GluR-mediated network excitability in hippocampal area CA3
To explore the functional implications of the observed changes in
receptor subunits, we monitored the excitability of CA3 networks in
105 horizontal hippocampal-entorhinal slices taken from 86 animals.
We compared both the baseline neuronal network oscillatory activity
(spontaneous gamma oscillations; SγO) in AMC vs. epileptic slices and
similar network activity following 100 nM kA application (kainate
gamma oscillations; KγO) in the same slices. The ratio of the power of
KγO:SγO was used as an indicator of the amount of AMPAR/KAR ex-
citation that could be produced in a given slice. Representative raw
traces and power spectra of both oscillation types are shown in Fig. 6A.
In slices from RISE rats at timepoint 1 (24h, SE), the SγO exhibited
concurrent high-frequency bursts and γ rhythm activity. In contrast,
oscillations in AMC slices (not shown) were more stable and synchro-
nized, remaining within a relatively narrow frequency band.
More specifically, analysis using the Morlet-wavelet spectrogram
revealed a mix of slow and fast oscillations in the RISE slices (Fig. 6A,
leftmost panel). Although SγO seemed abnormal in RISE rats just after
SE, the network was still responsive to 100 nM kA stimulation, which
caused a large increase in power and produced more coherent syn-
chronised oscillations (Fig. 6A, leftmost panel), comparable to those
observed in AMC slices in the presence of KA (see pooled data in
Fig. 6B). Interestingly, KA suppressed high-frequency activity in epi-
leptic slices.
Pooled data demonstrate that SγO mean peak power in the RISE SE
slices was comparable to AMC slices (36.6 ± 10.1 μV2, n=18, vs.
33.7 ± 6.8 μV2,n=13, ns) while the mean peak frequency was higher
than in the AMC slices (30.5 ± 1.1 Hz, n= 18, vs. 26.7 ± 0.8 Hz,
n=13, p < 0.05). In the presence of 100 nM kA, RISE SE slices
Fig. 2. Levels of receptor proteins in hippocampus that showed significant changes between AMC and RISE rats at different stages of epileptogenesis.
Top panels: Representative Western blots of hippocampal samples immunoblotted for the AMPAR subunits GluA1, GluA2 and GluA3, KAR subunit GluK2, NMDAR
subunit GluN2A, Group 1 metabotropic glutamate receptor subtype mGluR1α, and the GABAAR subunit β3. β-tubulin III, β-actin and α-GAPDH were used as loading
controls.
Bottom panels: Quantification of immunoreactive bands normalised to their respective loading controls. Bars represent the mean ± SD from 4 to 5 samples, with the
mean of the control group set to 1. *P < 0.05, **P < 0.01, ****P < 0.0001 vs Ctrl (Unpaired t-test).
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produced KγO similar to AMCs in mean peak power (3235 ± 1333
μV2, n=18, vs. 4024 ± 2191 μV2, n=13, p > 0.05), although
higher in mean peak frequency (36.2 ± 1.4 Hz, n=18, vs.
29.5 ± 1.4 Hz, n=13, p < 0.01) (Fig. 6B).
Our Western blots indicate that AMPAR subunits are profoundly
decreased in the hippocampus during the latent period. We therefore
specifically compared the SγO and KγO in RISE and AMC slices at this
timepoint. Under basal conditions in RISE slices the SγO was weak and
inconsistent over time, indicating underlying abnormalities of the net-
work function (Fig. 6A, middle panel). Moreover, spontaneous activity
was low in power but coherent gamma was observed, with a sharp peak
on the power spectrum, not normally characteristic of low-power SγO.
AMC slices, on the other hand, consistently exhibited strong SγO in
CA3, indicative of normal hippocampal neuronal network function
(Fig. 6A, middle panel).
When we challenged slices in the LP timepoint with KA, profound
differences in network excitability were apparent. In AMC slices,
100 nM kA elicited KγO with a dramatic increase in the power
compared to SγO, whereas in RISE slices KA did not significantly
change the network activity. Overall, RISE slices showed significantly
lower SγO power compared to AMC slices at this timepoint (20.6 ± 6.6
μV2, n=20, vs. 41 ± 11.5 μV2, n=18 p < 0.05), although oscilla-
tions were similar in mean peak frequency (34.9 ± 1.2 Hz, n= 20, vs.
35.4 ± 0.9 Hz, n=18 p > 0.05). Furthermore, KγO mean peak
power in RISE slices was considerably lower than in AMC slices during
LP (322.5 ± 156.7 μV2, n=20, vs. 1968 ± 756.8 μV2, n=18
p < 0.01), although no significant difference was observed in mean
peak frequency (36.4 ± 1.3 Hz, n= 20, vs. 34.6 ± 0.8 Hz, n=18
p > 0.05). Taken together these data support the contention that de-
creased AMPAR and KAR expression during the LP is associated with a
profound decrease in network excitability.
To determine whether rhythmic activity in the hippocampus un-
derwent further changes during epileptogenesis, we explored SγO and
KγO in slices from chronically epileptic rats (SRS) and compared them
to AMC. SγO demonstrated strong power in both control and epileptic
slices, although concurrently with gamma frequency SRS slices
Fig. 3. Levels of receptor proteins in temporal lobe that showed significant changes between AMC and RISE rats at different stages of epileptogenesis.
Top panels: Representative Western Blots of hippocampal samples blotted for AMPAR subunits (GluA1, GluA2 and GluA3), KAR subunit GluK5, NMDAR subunits
(GluN1, GluN2A, GluN2B), Group 1 metabotropic glutamate receptor subtypes (mGluR1α and mGluR5), and GABAAR subunit β3 (GABAA β3). β-actin and α-GAPDH
were used as loading controls.
Bottom panels: Quantification of immunoreactive bands normalised to their respective loading controls. Error bars represent the mean ± SD from 4 to 5 samples,
with the mean of the control group set to 1. *P < 0.05, **P < 0.01, ***P < 0.001 vs Ctrl (Unpaired t-test).
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exhibited transient high-frequency activity. When 100 nM KA was ap-
plied to pre-existing SγO, rhythmic activity dramatically increased in
power and became regular in both groups (Fig. 6, rightmost panel).
Moreover, in epileptic slices administration of KA abolished fast activity
and introduced a pure gamma frequency rhythm. The main parameters
of SγO were comparable in SRS vs. AMC slices (62.7 ± 9.6 μV2 at
35.9 ± 0.9 Hz, n=22, vs. 84.3 ± 23.9 μV2 at 36.3 ± 0.9 Hz, n=14,
p > 0.05), as shown in Fig. 6B. KγO, on the other hand, were sig-
nificantly stronger in power in SRS slices compared to AMC
(3401 ± 757.4 μV2, n= 22, vs. 1798 ± 612.7 μV2, n=14,
p < 0.05). There was no significant difference in the frequency of KγO
between epileptic and AMC slices (29.9 ± 0.8 Hz, n= 22, in RISE vs.
31.4 ± 0.4 Hz, n=14, in AMC, p > 0.05). These results suggest ele-
vated excitability of CA3, which may be linked to the appearance of
behavioural seizures during this period.
4. Discussion
Dysregulation of the inhibitory/excitatory balance leading to ex-
cessive excitatory synaptic transmission, synaptic reorganisation and
aberrant changes in neuronal circuits all contribute to the initiation and
onset of epilepsy (Bozzi et al., 2012). However, the profiles of how key
proteins change, which are important for insight into the mechanisms
of synaptic reorganisation and network reorganisation that lead to TLE
onset and maintenance, are not fully characterised. In this study, we
investigated how levels of specific proteins implicated in TLE change in
RISE rats during onset (SE), latent (LP) and chronic (SRS) phases of
epilepsy.
4.1. Synaptic marker proteins
Our data highlight alterations in the levels of synaptic markers in
both the hippocampus and temporal lobe during epileptogenesis. These
changes vary between the brain regions tested as well as the stage of
epilepsy, consistent with profound and dynamic changes in neuronal
network connectivity.
There were dramatic changes in PSD95 in the hippocampus during
epileptogenesis, not observed in the temporal lobe. At SE and LP stages
PSD95 was decreased but during SRS there was a 3-fold increase in
PSD95 compared to AMCs. The increase in PSD95 in chronic epilepsy
may be due to a reactive process driving the formation of more post-
synaptic components at each given presynaptic terminal. We con-
sidered that these changes might represent compensation for the loss of
AMPARs by providing more synaptic scaffolding for their recruitment,
but further analysis (Fig. 5) did not reveal a correlation between total
levels of AMPAR subunits and total levels of PSD95. The fact that we
did not see changes in synaptophysin is perhaps surprising since it is
well established that glutamatergic neurons in the hippocampus un-
dergo axonal sprouting during SRS. However, we analysed whole hip-
pocampi and sprouting does not occur across all subregions, being
confined mainly to dentate gyrus and some cells within CA1 (Esclapez
et al., 1999; Nadler et al., 1980).
In contrast to the decrease seen for PSD95, there was an increase in
gephyrin during the LP. Overall, we saw a rebound increase in ex-
citatory synapse marker during SRS with no change in inhibitory sy-
napse markers, consistent with electrophysiologically determined
changes in the excitation/inhibitory balance.
4.2. Glutamate receptors
The temporal profiles of changes in AMPAR subunits between hip-
pocampal and temporal lobe samples differed markedly. In the hippo-
campus GluA1 was decreased in all three phases of epilepsy, with only
very low levels present in LP and SRS. In contrast, in the temporal lobe,
GluA1 was only significantly decreased during the SRS phase. This
broadly agrees with a previous report of GluA1 downregulation in TLE
(Fukata and Fukata, 2017), and is consistent with dysfunctional reg-
ulation of GluA1 being an important factor in both epileptogenesis and
the spread of seizures across the brain.
In the hippocampus, GluA2 and GluA3 subunits were not decreased
immediately following SE but were both significantly reduced during LP
and SRS. In the temporal lobe GluA2 and GluA3 were reduced after SE,
though returned to AMC levels during LP. GluA1 and GluA2 subunits
were decreased during SRS, but GluA3 was not. Consistent with these
changes it has been reported recently that there are significant reduc-
tions in GluA1 and GluA2 in synaptosomal fractions from a KA-based
rat model of TLE (Egbenya et al., 2018). The complex patterns of
Fig. 4. Profile of expression level changes for each protein tested at dif-
ferent stages of epileptogenesis.
Ratio between average RISE and AMC immunoblot intensity values in both the
hippocampus and the temporal lobe. For each set of samples (SE, LP, SRS) the
mean value of the AMC immunoblots was set to 1 (dotted line) and the mean of
the corresponding RISE data plotted to illustrate the profile of change at dif-
ferent stages of epileptogenesis in the hippocampus and the temporal lobe.
(A) Ratio of GluA1, GluA2 and GluA3 subunit levels. (B) Ratio of GluK2 and
GluK5 subunit levels. (C) Ratio of GluN1, GluN2A and GluN2B subunit levels.
(D) Ratio of mGluR1α, mGluR5 and CB1 receptor levels. (E) Ratio of GABAA β3
subunit and gephyrin (inhibitory synapse marker) levels. (F) Ratio of sy-
naptophysin and PSD95 (excitatory synapse markers) levels.
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changes to individual subunits suggests dynamic rearrangement of
AMPAR composition and properties at different phases of epilepto-
genesis.
It should be noted, however, that a recent study has reported that
there are regional differences in AMPARs within the hippocampus
(Joshi et al., 2017). More specifically, in animals in self-sustaining
limbic SE the amplitudes of the miniature, spontaneous, and AMPA-
evoked excitatory currents recorded from the CA1 pyramidal neurons
were enhanced. The surface expression of GluA1 subunit-containing
AMPARs, assessed by biotinylation of hippocampal slices and sub-
sequent microdissection, was increased in the CA1 pyramidal neurons
whereas it was unchanged in dentate granule cells (DGCs) (Joshi et al.,
2017). Thus, it is possible that our use of the whole hippocampus for
total AMPAR subunit levels may overlook distinct changes in sub-re-
gions of the hippocampus. Future, more refined experiments are
therefore needed to assess how different AMPAR subunits are surface
expressed in the RISE model.
Kainate has long been used in epilepsy research to induce seizures
(Falcon-Moya et al., 2018). However, the only condition in which total
levels of the KAR subunit GluK2 were decreased was immediately fol-
lowing SE in the hippocampus. Levels of GluK5 were only significantly
decreased in the latent stage (LP) of epilepsy in the temporal lobe but
selective GluK5 antagonists have been reported to prevent convulsive
activity and seizures in pilocarpine-induced epilepsy (Smolders et al.,
2002). Thus, given the strong links between KARs and epilepsy, we
speculate that it is likely that changes in the number and/or stoichio-
metry of KARs at the cell surface, rather than the total amount of KAR
subunit protein, may be a determining factor in epileptogenesis.
We did not detect significant changes in any of the NMDAR subunits
immediately following SE, however, GluN2A was decreased in both the
hippocampus and temporal lobe during LP. GluN1 expression was also
decreased at this stage in the temporal lobe. Intriguingly, GluN2A re-
mained decreased in the hippocampus during SRS, while in the tem-
poral lobe both GluN2A and GluN2B were decreased. Different NMDAR
populations can have synaptic/extrasynaptic distributions and respond
differently to activity, which may provide a partial explanation for the
differential expression of NMDAR subunits highlighted in our analyses
(Sanz-Clemente et al., 2013). Overall our data from RISE suggest a
Fig. 5. Correlation between changes in receptors and synaptic marker proteins in hippocampus and temporal lobe at different stages of epileptogenesis.
(A) Scatterplot showing no correlation between levels of the pre-synaptic protein synaptophysin and GluK2 (KARs have both pre- and postsynaptic localisation) in
hippocampus (r=−0.921, p=0.2547, n= 5).
(B) Scatterplot showing no correlation between levels of the post-synaptic protein of excitatory synapses PSD95 and significantly altered post-synaptic receptor
subunits in hippocampus. GluA1 (r=−0.309, p=0.8000, n= 5), GluA2 (r=−0.7034, p= 0.5033, n= 5), GluA3 (r=−0.5376, p= 0.6387, n= 5), GluK2
(r= 0.9502, p= 0.2017, n= 5), GluN2A (r=−0.751, p=0.4591, n= 5), and mGluR1⍺ (r= 0.736, p= 0.4735, n=5).
(C) Scatterplot showing no correlation between gephyrin, a post-synaptic scaffold at inhibitory synapses, and levels of GABAAβ3 in hippocampus (r= 0.9875,
p= 0.1007, n=5).
(D) Scatterplot showing no correlation between levels of pre-synaptic protein synaptophysin and the KAR subunit GluK5 in temporal lobe (r= 0.5097, p= 0.6595,
n= 5).
(E) Scatterplot showing no correlation between levels of PSD95 and significantly altered post-synaptic receptor subunits in temporal lobe. GluA1 (r= 0.7936,
p= 0.4164, n= 5), GluA2 (r=−0.1451, p=0.9073, n=5), GluA3 (r= 0.3037, p=0.8036, n=5), GluK5 (r= 0.09309, p= 0.9406, n= 5), GluN1 (r= 0.7315,
p= 0.4777, n= 5), GluN2A (r=−0.7079, p=0.4993, n=5), GluN2B (r= 0.9824, p=0.1198, n= 5), mGluR1⍺ (r= 0.9415, p=0.2189, n=5), and mGluR5
(r= 0.8046, p= 0.4047, n= 5).
(F) Scatterplot showing no correlation between levels of gephyrin and GABAAβ3 in temporal lobe (r=−0.8509, p= 0.3521, n= 5).
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decrease in NMDAR mediated excitatory drive.
4.3. GABAARs
The GABAAβ3 subunit was decreased immediately following SE and
again in SRS in the hippocampus, and immediately following SE in the
temporal lobe. This is consistent with a loss of inhibitory input con-
tributing to the perturbation of excitatory/inhibitory balance and sei-
zure generation in SE. Many antiepileptic drugs function through
GABAergic mechanisms and evidence for altered GABAAR function
and/or subunit expression in epilepsy is well established. Consistent
with this, one interpretation of our data is that the changes we observed
could correspond to reported GABAAR internalization/degradation
during seizures (Goodkin et al., 2007; Kapur and Macdonald, 1997) that
may be related to the recognized loss of GABAergic interneurons which
underlies changes in excitability during epileptogenesis.
4.4. Network excitability
Our data strongly support the notion that changes in receptor ex-
pression are directly linked to alterations in network excitability. It is
tempting to speculate that loss of GluA1 in the latent period is at least
partly responsible for relative hypoexcitability in CA3 during this time.
Similarly, the increase in PSD95 may reflect a synaptic mechanism for
hyperexcitability at SRS, despite the lower expression of AMPAR sub-
units.
However, it is also possible that AMPAR hypofunction due to the
profound reduction in GluA1, GluA2 and GluA3 expression is directly
responsible for epileptiform activity. For example, in anti-AMPAR au-
toimmune encephalitis, antibodies generated against AMPAR epitopes
lead to AMPAR internalization and temporal lobe seizures in humans
(Gleichman et al., 2014; Haselmann et al., 2018; Lai et al., 2009). Si-
milarly, anti-NMDAR autoantibodies cause both receptor internalisation
and seizures (for review see (Dalmau et al., 2017)). Clearly, the balance
between excitation and inhibition in neuronal networks involves sub-
tleties that preclude simplistic classification of receptor changes as pro-
or anti-convulsant, for example, loss of excitatory drive to GABA in-
terneurons certainly has the potential to be an important mechanism for
seizure generation (Chun et al., 2019). Thus, even for AMPARs the role
(s) of different subunits and multiple post-translational modifications in
LTP, LTD and homeostatic synaptic up- and down-scaling are only just
being classified and understood in terms of ‘the AMPAR code’ (Diering
and Huganir, 2018). Further work on the role of AMPAR dynamics in
epileptogenesis will require detailed analyses at both cell- and synapse-
specific levels.
Finally, the loss of hippocampal GABAAβ3 when combined with
depressed expression of AMPAR and NMDAR subunits in the SRS phase
compared to LP, plus the much later timecourse of receptor changes to
temporal lobe structures, strongly supports the notion that epilepto-
genesis continues beyond the first seizure (Sloviter, 2005; Sloviter and
Bumanglag, 2013). These data indicate the importance of decreases in
GABAergic inhibition in the transition to spontaneous recurrent sei-
zures and, interestingly, very recent evidence suggests that selective
loss of interneurons alone could be sufficient to elicit seizures (Chun
et al., 2019).
Overall, our data, in combination with previous studies, suggest that
common changes occur in epilepsy patients and other rat models of
epilepsy, providing further evidence to suggest that the RISE model is a
convenient and representative experimental system.
In summary, our data demonstrate that there is a consistent and
Fig. 6. Electrophysiological analyses of network activity during epileptogenesis.
(A) Representative raw data traces of spontaneous (Sp) and KA-evoked (KA) gamma activity from each timepoint under study with associated power spectra and
Morlet-wavelet spectrograms in slices from epileptic groups. Scale bars for representative raw traces 200ms and 100 μV (right and left panels), 200ms and 50 μV
(middle panel).
(B) Summary box and whisker plots of pooled data from groups in each epileptic condition and from control groups. *P < 0.05, **P < 0.01 (Mann-Whitney test).
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reproducible change in the profile of key receptors in the RISE model of
temporal lobe epileptogenesis. Changes are specific to particular re-
ceptor subunits and do not correlate with decreases in synaptic mar-
kers, suggesting that these alterations are not attributable to synaptic
loss. Taken together, our results are consistent with the hypothesis that
the loss of inhibitory synaptic function, perhaps in addition to, or as a
consequence of, altered excitatory drive, contributes to the pathologi-
cally increased network activity in epilepsy. These results provide a
platform for future investigations targeting particular receptor subunits
to reduce or prevent seizures.
Disclosures
GW and BSH received financial support from GW Pharma. The other
authors declare no competing interests. We confirm that we have read
the Journal's position on issues involved in ethical publication and af-
firm that this report is consistent with those guidelines.
Acknowledgements
We are grateful to the BBSRC (JMH) and NC3Rs and GW Pharma
(GW) for funding. HIN and SG are Wellcome Trust funded PhD students.
BSH was funded by a GW PhD scholarship. We thank the Biomedical
Facility staff at Aston University for their assistance.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.neuropharm.2019.107728.
References
Badawy, R.A., Freestone, D.R., Lai, A., Cook, M.J., 2012. Epilepsy: ever-changing states of
cortical excitability. Neuroscience 222, 89–99.
Becker, A.J., 2018. Review: animal models of acquired epilepsy: insights into mechanisms
of human epileptogenesis. Neuropathol. Appl. Neurobiol. 44, 112–129.
Bozzi, Y., Casarosa, S., Caleo, M., 2012. Epilepsy as a neurodevelopmental disorder.
Front. Psychiatry 3, 19.
Busquets Garcia, A., Soria-Gomez, E., Bellocchio, L., Marsicano, G., 2016. Cannabinoid
Receptor Type-1: Breaking the Dogmas. F1000Res 5.
Chun, E., Bumanglag, A.V., Burke, S.N., Sloviter, R.S., 2019. Targeted hippocampal GABA
neuron ablation by Stable Substance P-saporin causes hippocampal sclerosis and
chronic epilepsy in rats. Epilepsia 60, e52–e57.
Dalmau, J., Geis, C., Graus, F., 2017. Autoantibodies to synaptic receptors and neuronal
cell surface proteins in autoimmune diseases of the central nervous system. Physiol.
Rev. 97, 839–887.
Devinsky, O., Vezzani, A., O'Brien, T.J., Jette, N., Scheffer, I.E., de Curtis, M., Perucca, P.,
2018. Epilepsy. Nat. Rev. Dis. Primers 4, 18024.
Diering, G.H., Huganir, R.L., 2018. The AMPA receptor code of synaptic plasticity.
Neuron 100, 314–329.
Egbenya, D.L., Hussain, S., Lai, Y.C., Xia, J., Anderson, A.E., Davanger, S., 2018. Changes
in synaptic AMPA receptor concentration and composition in chronic temporal lobe
epilepsy. Mol. Cell. Neurosci. 92, 93–103.
Esclapez, M., Hirsch, J.C., Ben-Ari, Y., Bernard, C., 1999. Newly formed excitatory
pathways provide a substrate for hyperexcitability in experimental temporal lobe
epilepsy. J. Comp. Neurol. 408, 449–460.
Evans, A.J., Gurung, S., Henley, J.M., Nakamura, Y., Wilkinson, K.A., 2017. Exciting
times: new advances towards understanding the regulation and roles of kainate re-
ceptors. Neurochem. Res. 44 (3), 572–584.
Falcon-Moya, R., Sihra, T.S., Rodriguez-Moreno, A., 2018. Kainate receptors: role in
epilepsy. Front. Mol. Neurosci. 11, 217.
Fukata, Y., Fukata, M., 2017. Epilepsy and synaptic proteins. Curr. Opin. Neurobiol.
45, 1–8.
Gleichman, A.J., Panzer, J.A., Baumann, B.H., Dalmau, J., Lynch, D.R., 2014. Antigenic
and mechanistic characterization of anti-AMPA receptor encephalitis. Ann. Clin.
Transl. Neurol. 1, 180–189.
Goodkin, H.R., Joshi, S., Kozhemyakin, M., Kapur, J., 2007. Impact of receptor changes
on treatment of status epilepticus. Epilepsia 48 (Suppl. 8), 14–15.
Haselmann, H., Mannara, F., Werner, C., Planaguma, J., Miguez-Cabello, F., Schmidl, L.,
Grunewald, B., Petit-Pedrol, M., Kirmse, K., Classen, J., Demir, F., Klocker, N., Soto,
D., Doose, S., Dalmau, J., Hallermann, S., Geis, C., 2018. Human autoantibodies
against the AMPA receptor subunit GluA2 induce receptor reorganization and
memory dysfunction. Neuron 100, 91–105 e109.
Henley, J.M., Wilkinson, K.A., 2016. Synaptic AMPA receptor composition in develop-
ment, plasticity and disease. Nat. Rev. Neurosci. 17, 337–350.
Joshi, S., Rajasekaran, K., Sun, H., Williamson, J., Kapur, J., 2017. Enhanced AMPA re-
ceptor-mediated neurotransmission on CA1 pyramidal neurons during status epi-
lepticus. Neurobiol. Dis. 103, 45–53.
Kapur, J., Macdonald, R.L., 1997. Rapid seizure-induced reduction of benzodiazepine and
Zn2+ sensitivity of hippocampal dentate granule cell GABAA receptors. J. Neurosci.
17, 7532–7540.
Lai, M., Hughes, E.G., Peng, X., Zhou, L., Gleichman, A.J., Shu, H., Mata, S., Kremens, D.,
Vitaliani, R., Geschwind, M.D., Bataller, L., Kalb, R.G., Davis, R., Graus, F., Lynch,
D.R., Balice-Gordon, R., Dalmau, J., 2009. AMPA receptor antibodies in limbic en-
cephalitis alter synaptic receptor location. Ann. Neurol. 65, 424–434.
Modebadze, T., Morgan, N.H., Peres, I.A., Hadid, R.D., Amada, N., Hill, C., Williams, C.,
Stanford, I.M., Morris, C.M., Jones, R.S., Whalley, B.J., Woodhall, G.L., 2016. A low
mortality, high morbidity reduced intensity status epilepticus (RISE) model of epi-
lepsy and epileptogenesis in the rat. PLoS One 11 e0147265.
Nadler, J.V., Perry, B.W., Gentry, C., Cotman, C.W., 1980. Loss and reacquisition of
hippocampal synapses after selective destruction of CA3-CA4 afferents with kainic
acid. Brain Res. 191, 387–403.
Paoletti, P., Bellone, C., Zhou, Q., 2013. NMDA receptor subunit diversity: impact on
receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci. 14, 383–400.
Perestenko, P.V., Henley, J.M., 2006. Visualization of AMPAR trafficking and surface
expression. In: Kittler, J.T., Moss, S.J. (Eds.), The Dynamic Synapse: Molecular
Methods in Ionotropic Receptor Biology, Boca Raton (FL).
Sanz-Clemente, A., Nicoll, R.A., Roche, K.W., 2013. Diversity in NMDA receptor com-
position: many regulators, many consequences. The Neuroscientist 19, 62–75.
Sendrowski, K., Sobaniec, W., 2013. Hippocampus, hippocampal sclerosis and epilepsy.
Pharmacol. Rep. 65, 555–565.
Sieghart, W., Savic, M.M., 2018. International union of basic and clinical pharmacology.
CVI: GABAA receptor subtype- and function-selective ligands: key issues in transla-
tion to humans. Pharmacol. Rev. 70, 836–878.
Sloviter, R.S., 2005. The neurobiology of temporal lobe epilepsy: too much information,
not enough knowledge. C R Biol. 328, 143–153.
Sloviter, R.S., Bumanglag, A.V., 2013. Defining "epileptogenesis" and identifying "anti-
epileptogenic targets" in animal models of acquired temporal lobe epilepsy is not as
simple as it might seem. Neuropharmacology 69, 3–15.
Smolders, I., Bortolotto, Z.A., Clarke, V.R., Warre, R., Khan, G.M., O'Neill, M.J., Ornstein,
P.L., Bleakman, D., Ogden, A., Weiss, B., Stables, J.P., Ho, K.H., Ebinger, G.,
Collingridge, G.L., Lodge, D., Michotte, Y., 2002. Antagonists of GLU(K5)-containing
kainate receptors prevent pilocarpine-induced limbic seizures. Nat. Neurosci. 5,
796–804.
Suh, Y.H., Chang, K., Roche, K.W., 2018. Metabotropic glutamate receptor trafficking.
Mol. Cell. Neurosci. 91, 10–24.
WHO, 2018. Epilepsy: Key Facts. WHO Fact Sheet.
H.I. Needs, et al. Neuropharmacology 158 (2019) 107728
9
